Want to see NCEL full AI Analyst Report?
NCEL Stock Chart & Stats
$2.66
--
Market closed
$2.66
--
Day’s Range― - ―
52-Week Range$1.83 - $28.03
Previous CloseN/A
VolumeN/A
Average Volume (3M)320.89K
Market Cap
$18.65M
Enterprise Value-$1.65M
Total Cash (Recent Filing)$2.20M
Total Debt (Recent Filing)$355.00K
Price to Earnings (P/E)―
Beta0.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,345,184
10 Day Avg. Volume34,320
30 Day Avg. Volume320,894
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.63
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit833.27
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$23.00Price Target Upside764.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (FDA Pre-IND)FDA alignment on CMC, preclinical safety and trial design materially de-risks the NCEL-101 program for months ahead. A successful Type B Pre-IND provides a clearer IND-enabling plan and reduces major regulatory uncertainty when progressing toward first-in-human studies.
Strengthened Scientific LeadershipAdding a globally recognized transplant pioneer enhances translational expertise, trial design credibility, and partner/investigator access. This durable boost to scientific leadership supports clinical development quality and helps attract collaborators and opinion-leader support.
Committed Near-term FinancingA priced private placement (with participation from existing shareholders) plus an equity line materially extends runway for IND-enabling work. This improves the company's ability to execute near-term development milestones and reduces immediate solvency pressure versus no funding.
Bears Say
No Revenue; Persistent LossesWith no product revenue, NewcelX remains fully pre-revenue and dependent on development milestones and financing. Persistent net losses indicate the business has not reached operating scale; without commercialization this structural gap will pressure capital needs for many quarters.
Negative Operating And Free Cash FlowCash burn has been consistently negative and closely tracks net losses, meaning losses are largely cash-based. This durable cash outflow pattern creates ongoing funding requirements and heightens execution risk until clinical milestones or revenue reduce burn.
Funding And Dilution Risk; Equity VolatilityAlthough debt is modest, swings in shareholders' equity and accumulated losses signal repeated reliance on equity raises. Structural reliance on dilution-prone financing pathways can erode ownership and may constrain strategic flexibility as development spending continues.
NewcelX News
NCEL FAQ
What was NewcelX’s price range in the past 12 months?
NewcelX lowest stock price was $1.83 and its highest was $28.03 in the past 12 months.
What is NewcelX’s market cap?
NewcelX’s market cap is $18.65M.
When is NewcelX’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NewcelX’s earnings last quarter?
Currently, no data Available
Is NewcelX overvalued?
According to Wall Street analysts NewcelX’s price is currently Undervalued.
Does NewcelX pay dividends?
NewcelX does not currently pay dividends.
What is NewcelX’s EPS estimate?
NewcelX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NewcelX have?
NewcelX has 5,345,184 shares outstanding.
What happened to NewcelX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NewcelX?
Currently, no hedge funds are holding shares in NCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NewcelX
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
NCEL Stock 12 Month Forecast
Average Price Target
$23.00
▲(764.66% Upside)